|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pikor LA, Ramnarine VR, Lam S and Lam WL:
Genetic alterations defining NSCLC subtypes and their therapeutic
implications. Lung Cancer. 82:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kerbel RS: Human tumor xenografts as
predictive preclinical models for anticancer drug activity in
humans: Better than commonly perceived-but they can be improved.
Cancer Biol Ther. 2 4 Suppl 1:S134–S139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
John T, Kohler D, Pintilie M, Yanagawa N,
Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA and Tsao MS:
The ability to form primary tumor xenografts is predictive of
increased risk of disease recurrence in early-stage non-small cell
lung cancer. Clin Cancer Res. 17:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin D, Wyatt AW, Xue H, Wang Y, Dong X,
Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, et al: High fidelity
patient-derived xenografts for accelerating prostate cancer
discovery and drug development. Cancer Res. 74:1272–1283. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson JI, Decker S, Zaharevitz D,
Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M,
Arbuck S, Hollingshead M and Sausville EA: Relationships between
drug activity in NCI preclinical in vitro and in vivo models and
early clinical trials. Br J Cancer. 84:1424–1431. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garber K: From human to mouse and back:
‘tumorgraft’ models surge in popularity. J Natl Cancer Inst.
101:6–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong X, Guan J, English JC, Flint J, Yee
J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, et al:
Patient-derived first generation xenografts of non-small cell lung
cancers: promising tools for predicting drug responses for
personalized chemotherapy. Clin Cancer Res. 16:1442–1451. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez
J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J and Ling YH:
Response and determinants of sensitivity to paclitaxel in human
non-small cell lung cancer tumors heterotransplanted in nude mice.
Clin Cancer Res. 6:4932–4938. 2000.PubMed/NCBI
|
|
12
|
Hao C, Wang L, Peng S, Cao M, Li H, Hu J,
Huang X, Liu W, Zhang H, Wu S, et al: Gene mutations in primary
tumors and corresponding patient-derived xenografts derived from
non-small cell lung cancer. Cancer Lett. 357:179–185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cech TR and Steitz JA: The noncoding RNA
revolution-trashing old rules to forge new ones. Cell. 157:77–94.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guttman M, Russell P, Ingolia NT, Weissman
JS and Lander ES: Ribosome profiling provides evidence that large
noncoding RNAs do not encode proteins. Cell. 154:240–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Bio. 14:699–712. 2013. View Article : Google Scholar
|
|
16
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun M, Nie FQ, Wang YF, Zhang Z, Hou J, He
D, Xie M, Xu L, De W, Wang Z and Wang J: LncRNA HOXA11-AS promotes
proliferation and invasion of gastric cancer by scaffolding the
chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res.
76:6299–6310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan JH, Liu XN, Wang TT, Pan W, Tao QF,
Zhou WP, Wang F and Sun SH: The MBNL3 splicing factor promotes
hepatocellular carcinoma by increasing PXN expression through the
alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol. 19:820–832.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Y, Lyu H, Liu H, Shi X, Song Y and Liu
B: Downregulation of the long noncoding RNA GAS5-AS1 contributes to
tumor metastasis in non-small cell lung cancer. Sci Rep.
6:310932016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao S, Lin Z, Li C, Wang Y, Yang L, Zou B,
Chen J, Li J, Song Z and Liu G: TFPI2AS1, a novel lncRNA that
inhibits cell proliferation and migration in lung cancer. Cell
Cycle. 16:2249–2258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Julien S, Merino-Trigo A, Lacroix L,
Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F,
Dartigues P, et al: Characterization of a large panel of
patient-derived tumor xenografts representing the clinical
heterogeneity of human colorectal cancer. Clin Cancer Res.
18:5314–5328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Braekeveldt N, Wigerup C, Tadeo I, Beckman
S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A,
Backman T, et al: Neuroblastoma patient-derived orthotopic
xenografts reflect the microenvironmental hallmarks of aggressive
patient tumours. Cancer Lett. 375:384–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lawrence MG, Pook DW, Wang H, Porter LH,
Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A,
et al: Establishment of primary patient-derived xenografts of
palliative TURP specimens to study castrate-resistant prostate
cancer. Prostate. 75:1475–1483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kageyama K, Ohara M, Saito K, Ozaki S,
Terai M, Mastrangelo MJ, Fortina P, Aplin AE and Sato T:
Establishment of an orthotopic patient-derived xenograft mouse
model using uveal melanoma hepatic metastasis. J Transl Med.
15:1452017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu LC, Allo G, John T, Li M, Tagawa T,
Opitz I, Anraku M, Yun Z, Pintilie M, Pitcher B, et al:
Patient-derived xenograft establishment from human malignant
pleural mesothelioma. Clin Cancer Res. 23:1060–1067. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abe T, Tada M, Shinohara N, Okada F, Itoh
T, Hamada J, Harabayashi T, Chen Q, Moriuchi T and Nonomura K:
Establishment and characterization of human urothelial cancer
xenografts in severe combined immunodeficient mice. Int J Urol.
13:47–57. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fichtner I, Rolff J, Soong R, Hoffmann J,
Hammer S, Sommer A, Becker M and Merk J: Establishment of
patient-derived non-small cell lung cancer xenografts as models for
the identification of predictive biomarkers. Clin Cancer Res.
14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reyal F, Guyader C, Decraene C, Lucchesi
C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P,
et al: Molecular profiling of patient-derived breast cancer
xenografts. Breast Cancer Res. 14:R112012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang D, Pham NA, Tong JF, Sakashita S,
Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, et al:
Molecular heterogeneity of non-small cell lung carcinoma
patient-derived xenografts closely reflect their primary tumors.
Int J Cancer. 140:662–673. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li H, Wheeler S, Park Y, Ju Z, Thomas SM,
Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, et al:
Proteomic characterization of head and neck cancer patient-derived
xenografts. Mol Cancer Res. 14:278–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bogner PN, Patnaik SK, Pitoniak R,
Kannisto E, Repasky E, Hylander B, Yendamuri S and Ramnath N: Lung
cancer xenografting alters microRNA profile but not
immunophenotype. Biochem Biophys Res Commun. 386:305–310. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crino L, Weder W, van Meerbeeck J and
Felip E: ESMO Guidelines Working Group: Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21 Suppl 5:v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Azzoli CG, Temin S, Aliff T, Baker S Jr,
Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L,
et al: 2011 focused update of 2009 American society of clinical
oncology clinical practice guideline update on chemotherapy for
stage IV non-small-cell lung cancer. J Clin Oncol. 29:3825–3831.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Junker K: Therapy-induced tumor regression
and regression grading in lung cancer. Pathologe. 35:574–577.
2014.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Filipits M, Pirker R, Dunant A, Lantuejoul
S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, et
al: Cell cycle regulators and outcome of adjuvant cisplatin-based
chemotherapy in completely resected non-small-cell lung cancer: The
international adjuvant lung cancer trial biologic program. J Clin
Oncol. 25:2735–2740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pierceall WE, Olaussen KA, Rousseau V,
Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker
R, Jiang C, et al: Cisplatin benefit is predicted by
immunohistochemical analysis of DNA repair proteins in squamous
cell carcinoma but not adenocarcinoma: Theranostic modeling by
NSCLC constituent histological subclasses. Ann Oncol. 23:2245–2252.
2012. View Article : Google Scholar : PubMed/NCBI
|
